The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InRoche Group reported a 6% increase in sales at constant exchange rates for the first quarter of 2026, fueled by robust demand for innovative medicines and diagnostics. However, the reported sales figures saw a 5% decline when measured in Swiss francs due to the significant appreciation of the local currency. The Pharmaceuticals Division was a key driver of growth, rising 7% at constant rates, with Vabysmo, Ocrevus, and Hemlibra leading the gains. These results highlight a stark contrast between strong underlying operational performance and the negative impact of currency headwinds. The company's outlook remains tied to its ability to sustain product momentum while navigating the challenges of a strong CHF. Overall, the report underscores Roche's operational resilience despite macroeconomic pressures affecting its reported financial totals.